RT
Rejuvenation Technologies
United States · Biotech
Rejuvenation Technologies develops targeted mRNA therapies intended to extend telomeres and restore cellular regenerative capacity in age-related disease.
Temporary telomere extension through mRNA delivery
The company uses modified mRNA delivered through proprietary lipid nanoparticles to extend telomeres temporarily, without permanent activation of telomerase. The approach is intended to support cellular regenerative capacity.
Its preclinical programmes target conditions including idiopathic pulmonary fibrosis and severe chronic liver disease.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Investment | Undisclosed | Jetstream Venture Fund — Role not disclosed |